Retinal detachment is separation of the neurosensory retina from the underlying retinal pigment epithelium. The most common cause is a retinal tear (rhegmatogenous detachment). Symptoms are decreased peripheral or central vision, often described as a curtain or dark cloud coming across the field of vision. Associated symptoms can include painless vision disturbances, including flashing lights and increased floaters. Traction and serous retinal detachments (not involving retinal tears) cause central or peripheral vision loss. Diagnosis is by funduscopy; ultrasonography may help determine the presence and type of retinal detachment if it cannot be seen with funduscopy. Immediate treatment is imperative if rhegmatogenous retinal detachment is acute and threatens central vision. Treatment of rhegmatogenous detachment may include sealing retinal holes (by laser or cryotherapy), supporting the holes with scleral buckling, pneumatic retinopexy, and/or vitrectomy.
There are 3 types of detachment: rhegmatogenous, which involves a retinal tear, traction, and serous (exudative) detachment. Traction and serous retinal detachments do not involve a tear and are thus called nonrhegmatogenous.
Rhegmatogenous detachment is the most common. Risk factors include the following:
Traction retinal detachment can be caused by vitreoretinal traction due to preretinal fibrous membranes as may occur in proliferative diabetic or sickle cell retinopathy.
Serous detachment results from transudation of fluid into the subretinal space. Causes include severe uveitis, especially in Vogt-Koyanagi-Harada disease, choroidal hemangiomas, and primary or metastatic choroidal cancers (see Cancers Affecting the Retina).
Symptoms and Signs
Retinal detachment is painless. Early symptoms of rhegmatogenous detachment may include dark or irregular vitreous floaters (particularly a sudden increase, flashes of light (photopsias), and blurred vision. As detachment progresses, the patient often notices a curtain, veil, or grayness in the field of vision. If the macula is involved, central vision becomes poor. Patients may have simultaneous vitreous hemorrhage. Traction and serous (exudative) retinal detachments can cause blurriness of vision, but they may not cause any symptoms in the early stages.
Retinal detachment should be suspected in patients, particularly those at risk, who have any of the following:
Indirect ophthalmoscopy shows the retinal detachment and can differentiate the subtypes of retinal detachment in nearly all cases. Direct funduscopy using a handheld ophthalmoscope can miss some retinal detachments, which may be peripheral. Peripheral fundus examination, using either indirect ophthalmoscopy with scleral depression or using a 3-mirror lens, should be done.
If vitreous hemorrhage (which may be due to a retinal tear), cataract, corneal opacification, or traumatic injury obscures the retina, retinal detachment should be suspected and B-scan ultrasonography should be done.
Although often localized, retinal detachments due to retinal tears can expand to involve the entire retina if they are not treated promptly. Any patient with a suspected or established retinal detachment should be examined urgently by an ophthalmologist.
Rhegmatogenous detachment is treated with one or more methods, depending on the cause and location of the lesion. One method involves sealing the retinal holes by laser or cryotherapy. The eye may be treated by scleral buckling (which indents the sclera, pushing the retina inward thereby relieving vitreous traction on the retina). During this procedure, fluid may be drained from the subretinal space. Pneumatic retinopexy (intravitreal injection of gas) and vitrectomy are other treatments. Retinal tears without detachment can be sealed by laser photocoagulation or transconjunctival cryopexy. Nearly all rhegmatogenous detachments can be reattached surgically.
Nonrhegmatogenous detachments due to vitreoretinal traction may be treated by vitrectomy; transudative detachments due to uveitis may respond to systemic corticosteroids, systemic immunosuppression (eg, methotrexate, azathioprine, anti-TNF drugs), or a slow-release corticosteroid implant, which is surgically implanted into the eye. Primary and metastatic choroidal cancers also require treatment. Choroidal hemangiomas may respond to localized photocoagulation or photodynamic therapy.
Last full review/revision December 2012 by Sunir J. Garg, MD, FACS
Content last modified October 2013